专题：PI3K/AKT/mTOR signaling in cancer

This cluster of papers focuses on the mTOR signaling pathway, particularly its role in growth control, metabolism, and disease, with a specific emphasis on cancer. The PI3K/AKT pathway, Raptor, TSC2, and rapamycin are central to the research discussed in these papers.
最新文献
Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation

article Full Text OpenAlex

PI3K/Akt/mTOR pathway expression profiling reveals age- and subtype-specific molecular heterogeneity in the Nigerian breast cancer landscape

article Full Text OpenAlex

Inhibition of GRK2 mitigates cisplatin‐induced acute and chronic nephrotoxicity by targeting the NADPH oxidase 4/oxidative stress axis

article Full Text OpenAlex

Nuclear phosphoinositide signaling in cell biology and disease

article Full Text OpenAlex

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors

article Full Text OpenAlex

Abstract RF7-04: Gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+/HER2-/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trial

article Full Text OpenAlex

Abstract RF7-02: Alpelisib plus fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor (EPIK-B5): Phase III, randomized, double-blind, placebo-controlled, multicenter study

article Full Text OpenAlex

Abstract RF7-05: Capivasertib plus fulvestrant in hormone receptor-positive (HR+) advanced breast cancer (ABC): exploratory ctDNA analyses from the Phase 3 CAPItello-291 trial

article Full Text OpenAlex

Neurosurgical strategies in mTORopathies: from resection to disconnection and laser ablation

article Full Text OpenAlex

Structure and function of the yeast amino acid-sensing SEAC–EGOC supercomplex

article Full Text OpenAlex

近5年高被引文献
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

review Full Text OpenAlex 1801 FWCI266.8954

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

review Full Text OpenAlex 792 FWCI117.7143

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

review Full Text OpenAlex 751 FWCI62.2274

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

article Full Text OpenAlex 666 FWCI164.4328

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

article Full Text OpenAlex 477 FWCI70.9057

mTOR substrate phosphorylation in growth control

review Full Text OpenAlex 413 FWCI33.2804

Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update

review Full Text OpenAlex 351 FWCI140.202

EGFR signaling pathway as therapeutic target in human cancers

review Full Text OpenAlex 322 FWCI42.4804

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

article Full Text OpenAlex 302 FWCI23.7814

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

article Full Text OpenAlex 300 FWCI65.1546